The FDA’s approval on Thursday of Madrigal Pharmaceutical’s Rezdiffra (resmetirom) is the first for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis).

Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation.

NASH (formerly MASH — metabolic dysfunction-associated steatohepatitis) is a result of the progression of nonalcoholic fatty liver disease where liver inflammation can lead to liver scarring and liver dysfunction. By at least one estimate, approximately 6-8 million people in the U.S. have NASH with moderate to advanced liver scarring. Rezdiffra is expected to be available to patients in the U.S. in April.

Read the FDA announcement here.

To read the whole story, click here to subscribe.

Related Topics